Navigation Links
3 postulates to help identify the cause of Alzheimer's disease
Date:6/20/2011

Amsterdam, The Netherlands, June 20, 2011 -- After more than 100 years following its pathologic description, the cause of Alzheimer's disease (AD) remains unknown. To test the validity of present and future proposals related to the probable cause of AD, three postulates, or necessary conditions, are recommended by Jack de la Torre, MD, PhD, Adjunct Professor of Psychology at the University of Texas, Austin, in an article published in the Journal of Alzheimer's Disease.

"Knowing what causes AD is critically important because it would allow more effective therapy to specifically prevent new cases and apply interventions to slow down the mental decline in people who already have this dementia," commented Dr. de la Torre. "In search of the Alzheimer cause, a considerable number of hypothetical proposals have been published, but no proposal so far has reached a consensus of agreement by experts in the field. Proposals regarded as weak and insubstantial by evidence-based medicine not only cost lots of money and effort, they also hinder clinical progress."

Dr. de la Torre believes that any likely cause of AD would need to satisfy the criteria established by the three postulates when hypothetical proposals are submitted to explain the pathogenesis of AD. The first postulate requires that the cause of AD precedes the cognitive decline and neurodegenerative pathology that characterize AD. This rule identifies a primary event from a neuropathological effect generated by the disease process. The second postulate stipulates that interventions aimed at the proposed causal event should prevent or reverse the cognitive and neurodegenerative pathology associated with AD prior to disease onset. This postulate emphasizes prevention or reversal of emerging neurocognitive pathology considerably before AD onset. If the first and second postulate requirements are met, the third postulate follows that interventions targeting the causal event should significantly lower the incidence of AD.

To evaluate the potential usefulness of the three postulates, Dr. de la Torre examined seven mainstream proposals offered as the cause of AD and explored their relative merit or lack of merit on Alzheimer patients. Proposals included the amyloid-β, cell cycle, cholinergic, inflammatory, oxidative stress, tau, and vascular hypotheses.

Dr. de la Torre analyzed evidence of efficacy for each proposal obtained from high-quality clinical trials, then assessed whether such evidence met the requirements posed by each postulate. Only two of the seven proposals examined, the vascular hypothesis and the oxidative stress hypothesis, partially met the requirements of one or two but not all three postulates.

Dr. de la Torre concludes that "By questioning or helping validate a proposed cause-effect relationship to AD, the three postulates I have described may serve as a primary instrument in targeting efficient therapeutic initiatives designed to prevent, reverse, or slow down the likely cause of this dementia."


'/>"/>

Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. UNT Health Science Centers Roby Helps Identify Bodies of Chiles Patio 29
2. Scientists identify microRNA as possible cause of chemotherapy resistance
3. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
4. Study to Identify Infants at High Risk for Developing Obesity
5. Mount Sinai researchers are the first to identify heart abnormalities in World Trade Center workers
6. Researchers Identify 2 Genes Linked to Fatty Liver Disease
7. Researchers identify potential new target for treating hepatitis C
8. Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Blood test may identify lung cancer patients likely to respond to erlotinib
11. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: